Alzinova AB (publ) announces that the Company has recruited Kirsten Harting as new Chief Medical Officer. The role includes overall responsibility for the continued clinical development of the drug candidate ALZ-101 and the antibody ALZ-201. Kirsten will be part of the Company's management team and will start her position on August 14, 2023.

Alzinova works with the development of Alzheimer's drugs and has developed a unique approach to counteract the disease that can have a major impact on the care and prevention of Alzheimer's disease. The Company's goal is to take its drug candidates through clinical studies and to the market and become a market leader in the treatment of the disease. Alzinova is now taking another important step in this direction by recruiting Kirsten Harting as Chief Medical Officer.

Kirsten Harting has a medical degree, an executive MBA from Copenhagen Business School and more than 30 years of experience in medicine, clinical studies and drug development as well as business development and bringing products to market from Lundbeck, Pfizer, ALK and Novo Nordisk, among others. Kirsten comes from the role as Senior Medical Director at Cytoki Pharma and will start her position as CMO at Alzinova on August 14, 2023.